Sarilumab with three immunotherapy drugs for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests whether adding sarilumab (an immune-blocking medicine) to three immunotherapy medicines can shrink unresectable, advanced melanoma that cannot be removed with surgery. It aims to improve how well the immune system controls the cancer, especially in Stage III or Stage IV disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed melanoma that is Stage IIIb, IIIc, IIId, or Stage IV and cannot be fully removed by surgery
- You have not had prior cancer treatment for metastatic (spread) melanoma, with limited exceptions
- You can complete study visits, blood tests, and required tumor biopsies and scans on the schedule
- Your recent scans (within 4 weeks) show measurable disease, and you can provide the baseline scan images
- You do not have untreated brain metastases or certain melanoma types like ocular (eye) melanoma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This study tests a combination of two immunotherapy drugs (nivolumab and relatlimab) for people with advanced melanoma that cannot be removed by surgery or has spread. These drugs help your immune system fight the cancer more effectively.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.